Geneva, Feb. 2 -- International Clinical Trials Registry received information related to the study (ChiCTR2600117338) titled 'Cadonilimab combined with gemcitabine plus carboplatin in metastatic triple-negative breast cancer: a single-arm, multicenter, phase II clinical study' on Jan. 22.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Sun Yat-sen University Cancer Center
Condition:
advanced triple-negative breast cancer
Intervention:
treatment group: Cadonilimab: 10 mg/kg, ivgtt, first 60 minutes followed by 30 minutes if tolerated, d1, every 3 weeks
Gemcitabine: 1.4mg/m2, ivgtt, 30 minutes, day 1, 8, every 3 weeks
Recruitment Status: Recruiting
Phase: 2
Date of First Enrollment: 2025-02-19
Targe...